gp 1-515 has been researched along with 3,7-dimethyl-1-propargylxanthine in 1 studies
| Studies (gp 1-515) | Trials (gp 1-515) | Recent Studies (post-2010) (gp 1-515) | Studies (3,7-dimethyl-1-propargylxanthine) | Trials (3,7-dimethyl-1-propargylxanthine) | Recent Studies (post-2010) (3,7-dimethyl-1-propargylxanthine) |
|---|---|---|---|---|---|
| 8 | 0 | 0 | 202 | 1 | 23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cronstein, BN; Firestein, G; Naime, D | 1 |
1 other study(ies) available for gp 1-515 and 3,7-dimethyl-1-propargylxanthine
| Article | Year |
|---|---|
The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine.
Topics: Adenosine; Adenosine Deaminase; Adenosine Kinase; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Female; Leukocytes; Mice; Mice, Inbred BALB C; Purinergic P1 Receptor Antagonists; Ribonucleosides; Theobromine; Tumor Necrosis Factor-alpha; Xanthines | 1995 |